Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
The widespread clinical use of immune checkpoint inhibitors (ICI) has increased our knowledge on their adverse effects on chronic inflammatory diseases. Atherosclerosis, a low-grade lipid-driven inflammatory disease of the larger arteries, is commonly present in cancer patients. A major concern is t...
Saved in:
| Main Authors: | Esther Lutgens, Tom T.P. Seijkens |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000300.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem
by: Esther Lutgens, et al.
Published: (2021-06-01) -
Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01) -
Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors
by: Xinyue Han, et al.
Published: (2025-01-01) -
Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors
by: Qi Zhang, et al.
Published: (2024-12-01) -
Impact of natremia on metastatic non small cell lung cancer patients receiving immune checkpoint inhibitors
by: Martina Catalano, et al.
Published: (2024-11-01)